Cadila gets US FDA approval for Promethazine tablets

by Medindia Content Team on  November 21, 2005 at 5:31 PM Drug News   - G J E 4
Cadila gets US FDA approval for Promethazine tablets
Cadila Healthcare Ltd has received US Food Drug Administration (US FDA) approval to market Promethazine tablets 12.5 mg, 25 mg and 50 mg in the US.

Promethazine is an anti-emetic drug, used to treat allergic symptoms and reactions, to cause sedation, to assist in controlling postoperative pain and to control motion sickness.

The company plans to launch the drug in US this year. The US market for this drug is estimated at $116 million. The group had recently received approval to market Ribavirin capsules in the US market through its US subsidiary Zydus Pharmaceuticals Inc, it added.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All